Acute Toxicological Profile of Pharmaceutical-Grade Nicotinamide Riboside: A Route-Dependent Assessment Across Intravenous, Intramuscular, and Subcutaneous Administration

No abstract is available for this paper.

• Publication year

  2026

• Venue

  bioRxiv

• Publication date

  2026-03-02

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.64898/2026.02.27.708010
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Randomized, placebo-controlled, pilot clinical study evaluating acute Niagen+ IV and NAD+ IV in healthy adults

  2024cited by this paper
• Intravenous nicotinamide riboside elevates mouse skeletal muscle NAD+ without impacting respiratory capacity or insulin sensitivity

  2022cited by this paper
• Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults

  2019influential reference
• Quantitative Analysis of NAD Synthesis-Breakdown Fluxes.

  2018cited by this paper
• Safety assessment of nicotinamide riboside, a form of vitamin B3

  2016cited by this paper
• Nicotinamide riboside is uniquely and orally bioavailable in mice and humans

  2016cited by this paper
• The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection

  2015cited by this paper
• Guidance for Industry Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers

  2005cited by this paper

• No citing papers are available for this paper.